文献速递神经肿瘤

曲美替尼治疗进展性儿童低级别胶质瘤的疗效分析

Response to trametinib treatment in progressive pediatric low-grade glioma patients.
PubMed 文献 · J Neurooncol · 2020-10-07

这项多中心回顾性中枢阅片研究分析了2015至2019年间18例接受MEK抑制剂曲美替尼个体化治疗的进展性儿童低级别胶质瘤患者。中枢影像评估显示6例部分缓解、2例轻微缓解、10例疾病稳定,治疗期间疾病控制率达100%;但16/18例出现治疗相关不良事件,8/18例发生严重不良事件,停药后3例在中位3个月内出现疾病进展。

要点

  • 曲美替尼治疗进展性pLGG疾病控制率达100%,6例部分缓解。
  • KIAA1549:BRAF融合及NF1驱动肿瘤均观察到治疗反应。
  • 治疗相关不良事件发生89%,严重不良事件44%,需密切监测。

核心结论

  • 曲美替尼对进展性儿童低级别胶质瘤具有活性且可行,所有患者均获疾病控制。
  • 治疗相关毒性干扰了个体化治疗,且停药后部分患者疾病控制未持续。
  • 数据支持MEK抑制剂在pLGG中的类效应,并提示需开展曲美替尼对比现行标准化疗的一线随机试验。

研究设计与样本

  • 多中心回顾性、中枢影像集中阅片研究,分析2015至2019年间18例接受曲美替尼个体化治疗的进展性pLGG患者。
  • 评估中枢影像学反应、分子分型及研究者观察到的毒性。

主要发现

  • 最佳总体反应为6例部分缓解、2例轻微缓解、10例疾病稳定,治疗期间疾病控制率100%。
  • KIAA1549:BRAF驱动及NF1驱动肿瘤中均观察到治疗反应。
  • 中位治疗时间12.5个月(范围2至27个月)。
  • 停药后3例患者在中位3个月(范围2至4个月)内出现疾病进展。
  • 治疗相关不良事件发生于16/18例(89%),8/18例(44%)发生严重不良事件(CTCAE III和/或IV级,最常见为皮疹和甲沟炎),6/18例(33%)需减量,2/18例(11%)需停药。

临床怎么用

  • 曲美替尼可作为进展性pLGG的个体化治疗选择,治疗期间需密切监测皮肤皮疹和甲沟炎等毒性。
  • 部分患者需减量或停药,停药后应警惕短期内疾病进展并加强影像随访。

局限性

  • 回顾性研究、样本量小(18例),个体化治疗决策可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A hallmark of pediatric low-grade glioma (pLGG) is aberrant signaling of the mitogen activated protein kinase (MAPK) pathway. Hence, inhibition of MAPK signaling using small molecule inhibitors such as MEK inhibitors (MEKi) may be a promising strategy. METHODS: In this multi-center retrospective centrally reviewed study, we analyzed 18 patients treated with the MEKi trametinib for progressive pLGG as an individual treatment decision between 2015 and 2019. We have investigated radiological response as per central radiology review, molecular classification and investigator observed toxicity. RESULTS: We observed 6 partial responses (PR), 2 minor responses (MR), and 10 stable diseases (SD) as best overall responses. Disease control rate (DCR) was 100% under therapy. Responses were observed in KIAA1549:BRAF- as well as neurofibromatosis type 1 (NF1)-driven tumors. Median treatment time was 12.5 months (range: 2 to 27 months). Progressive disease was observed in three patients after cessation of trametinib treatment within a median time of 3 (2-4) months. Therapy related adverse events occurred in 16/18 patients (89%). Eight of 18 patients (44%) experienced severe adverse events (CTCAE III and/or IV; most commonly skin rash and paronychia) requiring dose reduction in 6/18 patients (33%), and discontinuation of treatment in 2/18 patients (11%). CONCLUSIONS: Trametinib was an active and feasible treatment for progressive pLGG leading to disease control in all patients. However, treatment related toxicity interfered with treatment in individual patients, and disease control after MEKi withdrawal was not sustained in a fraction of patients. Our data support in-class efficacy of MEKi in pLGGs and necessity for upfront randomized testing of trametinib against current standard chemotherapy regimens.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Selt F, van Tilburg CM, Bison B, et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. J Neurooncol. 2020. PMID: 33026636. doi:10.1007/s11060-020-03640-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。